J. Morales-Garcia, V. Palomo, M. Redondo, S. Alonso-Gil, C. Gil, A. Martinez, A. Perez-Castillo. Crosstalk between phophodiesterase 7 and glycogen synthase kinase 3, two relevant therapeutic targets for neurological disorders. ACS Chem. Neurosci., 5, 194-204 (2014). doi: 10.1021/cn400


J. Mora, A. Rodríguez-Mahillo, C. Gil, Y. Morón, I. Moneo, A. Martínez, M. Gonzalez-Muñoz. Glycogen synthase kinase-3β expression and phosphorylation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.British J. Med. & Med. Sci., 4, 263-271 (2014)


A. Martinez, D.I. Perez, C. Gil.Lessons learnt from Glycogen synthase kinase 3 inhibitors development on Alzheimer’s Disease. Curr. Topics Med. Chem., 13, 1808-1810 (2013)


A. Martinez, C. Gil.Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson’s Disease, in Emerging drugs and targets for Parkinson ’s disease. A. Martinez & C. Gil, Eds., RSC Drug Discovery series, RSC, Cambridge 2013, pp 294-307. (ISBN 978-1-84973-617-6)


R. Perez, C. Pascual, D. Antequera, M. Bolos, M. Redondo, V. Perez-Grijalba, D.I. Perez, M. Sarasa, A. Krzyzanowska, C. Gil, I. Ferrer, A. Martinez, E. Carro.Reduction of cognitive impairment and pathological hallmarks in a mouse model of Alzheimer disease by Phosphodiesterase 7 inhibitor treatment. Neurobiol. Aging, 34, 2133-45, (2013)doi: pii:S0197-4580(13)00111-5. 10.1016/j.neurobiolaging.2013.03.011


C. Gonzalez-Garcia, B. Bravo, A. Ballester, R Gomez-Perez, C. Eguiluz, M. Redondo, A. Martinez, C. Gil, S. Ballester.Comparative assessment of PDE4 and 7 inhibitors as therapeutic agents in EAE. British J. Pharmacol, 170, 602-613 (2013), doi: 10.1111/bph.12308


E. Beurel, O. Kaidanovich-Beilin, W. Yeh, L. Song, S.M. Michalek, V. Palomo,J.R. Woodgett, L.E. Harrington, H. Eldar-Finkelman, A. Martinez, R.S. Jope. Regulation of Th1 cells and experimental autoimmune encephalomyelitis (EAE) by glycogen synthase kinase-3. J. Inmmunol., 190, 5000-5011 (2013)


J. A. Morales-Garcia, C. Susín, S. Alonso-Gil, D.I. Pérez, V. Palomo, C. Pérez, S. Conde, A. Santos, C. Gil, A. Martinez, A. Perez-Castillo. Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.ACS Chem. Neurosci., 4, 350-360 (2013), doi: 10.1021/cn300182g.


E. Medina-Rodriguez, F.J. Arenzana, J. Pastor, M. Redondo, V. Palomo, R. Garcia de Sola, C. Gil, A. Martinez, A. Bribian. F. de Castro.Inhibition of endogenous Phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.Cel. Mol. Life Sci., 70, 3449-3462 (2013),doi: 10.1007/s00018-013-1340-2.


T.V. Lipina, V. Palomo, C.Gil, A. Martinez, J.C. Roder.Dual inhibitor of PDE7 and GSK-3, VP1.15, acts as antipsychotic and cognitive enhancer in C57BL/6J mice.Neuropharmacol. 64, 205-214 (2013), doi: 10.1016/j.neuropharm.2012.06.032.


M. Redondo, V. Palomo, J. Brea, D.I. Perez, R. Martín-Alvarez, N. Paul-Fernandez, M.I. Cadavid, M.I. Loza, C. Perez, G. Mengod, A. Martinez, C. Gil, N. Campillo.Identification in silico and experimental validation of novel PDE7 inhibitors with effect in EAE mice.ACS Chem. Neurosci., 3, 793-803 (2012),dx.doi.org/10.1021/cn.300105c


C. Susín, J. A. Morales-Garcia, D. Aguilar-Morante, V. Palomo, M. Sanz-SanCristobal, S. Alonso-Gil, C. Gil, A. Santos, A. Martinez, A. Perez-Castillo.The new iminothiadiazole derivative VP1.14, ameliorates hippocampal damage after an excitotoxic injury.J Neurochem, 122, 1193-1202 (2012). doi: 10.1111/j.1471-4159.2012.07866.x.


J. A. Morales-Garcia, R. Luna-Medina, S. Alonso-Gil, M. Sanz-SanCristobal, V. Palomo, C. Gil, A. Martinez, A. Santos and A. Perez-Castillo.Glycogen synthase kinase 3 b inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.ACS Chem. Neurosci., 3, 963-971 (2012),doi:10.1021/cn.300110c


M. Redondo, J. Brea, D.I. Perez, I. Soteras, C. Val, C. Pérez, J.A. Morales, S. Alonso-Gil, N. Paul-Fernandez, R. Martin-Alvarez, I. Cadavid, I. Loza, A. Perez-Castillo, G. Mengod, N.E. Campillo, A. Martínez, C. Gil.Effects of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.J. Med. Chem., 55, 3274-3284 (2012)


V. Palomo, D. I. Perez, C. Perez, J. A. Morales-Garcia, I. Soteras, S. Alonso-Gil, A. Encinas, A. Castro, N. E. Campillo, A. Perez-Castillo, C. Gil, A. Martinez.5-Imino-1,2-4-thiadiazoles: First Small Molecules as substrate competitive inhibitors of Glycogen Synthase Kinase 3. J. Med. Chem., 55, 1645-1661 (2012)


D. I. Perez; M. Pistolozzi; V. Palomo; M. Redondo; C. Fortugno; C. Gil; G. Felix; A. Martinez; C. Bertucci.5-Imino-1,2-4-thiadiazoles and Quinazolines derivatives as Glycogen synthase kinase 3β (GSK-3β) and Phosphodiesterase 7 (PDE7) inhibitors: Determination of Blood brain barrier penetration and binding to human serum albumin.Eur. J. Pharm. Sci., 47, 175-185 (2012)


H. Eldar-Finkelman, A. Martinez.Glycogen synthase kinase 3 inhibitors: Preclinical and clinical focus on CNS.Front. Mol. Neurosci., 4:32 (2011)


Crouch P, Cole A, Cousin M, Martinez A, Kanninen K.Glycogen synthase kinase 3.Int. J. Alzh. Dis.,2011:279234 (2011)


A. Martinez, C. Gil, D.I. Perez.Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer ’s disease treatment. Int. J. Alzh. Dis., 2011:280502 (2011)


V. Palomo, D.I. Perez, C. Gil, A. Martinez.The potential role of Glycogen synthase kinase 3 inhibitors in the treatment of amyotrophic lateral sclerosis.Curr. Med. Chem., 18, 3028-3024 (2011)


V. Palomo, I. Soteras, D.I. Perez, C. Perez, C. Gil, NE. Campillo, A. Martinez.Exploring the binding sites of Glycogen Synthase Kinase 3. Identification and characterization of allosteric modulation cavities.J. Med. Chem., 54, 8461-8470 (2011)


D.I. Perez, V. Palomo, C. Perez, C. Gil, P. Dansk, FJ. Luque, S. Conde, A. Martinez, Switching reversibility to irreversibility in GSK-3 inhibitors: Clues for specific design of new compounds.J. Med. Chem., 54, 4042-4056 (2011)


JA Morales, M Redondo, C Gil, C. Perez, S Alonso-Gil, A Martinez, A Santos, A Perez-Castillo. Phosphodiesterase 7 (PDE7) inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease.PLoS ONE, 6(2): e17240 (2011)


I. Paterniniti, E. Mazzon, D. Impellizzeri, M. Redondo, D.I. Perez, C. Gil, E. Esposito, A. Martinez S. Cuzzocrea. Phosphodiesterase 7 (PDE7) inhibitors as new potential drugs for the therapy of spinal cord injury. PLoS ONE, 6(1): e15937 (2011)


D.I. Perez, C. Gil, A. Martínez. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med. Res. Rev. 31, 924-954 (2011)


D.I. Perez, S. Conde, C. Pérez, C. Gil, D. Simon, F. Wandosell, F.J. Moreno, J.L. Gelpí,F.J. Luque, A. Martínez. Thienylhalomethylketones: Irreversible GSK-3 Inhibitors as Useful Pharmacological Tools. Bioorg. Med. Chem. 17, 6914-6925(2009)


D.I. Perez, A. Martinez, GSK-3 inhibitors: A ray of hope for the treatment of Alzheimer’s disease?. J. Alzheimer Dis. 15, 181-191 (2008)


C. Gil, N.E. Campillo, D.I. Perez, A. Martinez.Phosphodiesteresae 7 (PDE7) inhibitors as new drugs for neurological and anti-inflammatory disorders.Exp. Opin. Ther. Patents 18, 1127-1139 (2008)


A. Martinez.Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs.Med. Res. Rev. 28, 773-796 (2008)